EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

SSTR-directed peptide receptor radionuclide therapy for recurrent meningiomas: analysis of safety, efficacy and prognostic factors

Natalie Hasenauer iD, Miriam Müller, Heribert Hänscheid, Sebastian E Serfling, Kerstin Michalski, Marieke Heinrich, Bülent Polat, Andreas K Buck, Rudolf A Werner, Philipp E Hartrampf

European Journal of Nuclear Medicine and Molecular Imaging · 2025-12 · 53 (1) · 116-127

DOI: 10.1007/s00259-025-07336-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 02.06.2025. Verfasst von Natalie Hasenauer und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, University Hospital Würzburg, Oberdürrbacherstraße 6, 97080, Würzburg, Germany. Hasenauer_N@ukw.de. Hauptthemen laut MEDLINE: Meningioma, Receptors, Somatostatin, Octreotide, Meningeal Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Würzburg.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

This study evaluates safety and efficacy of peptide receptor radionuclide therapy (PRRT) as a stand-alone treatment for recurrent meningiomas and investigates the prognostic value of laboratory markers and quantitative PET parameters.

Methods

The single-center study includes 32 patients with recurrent meningioma, who underwent PRRT with [ 177 Lu]Lu-DOTATOC/-TATE. Pre-treatment assessments comprised [ 68 Ga]Ga-DOTATOC PET imaging, routine hematology and serum chemistry analysis. Outcomes including progression-free survival (PFS), overall survival (OS), and treatment related toxicity, were retrospectively evaluated using Kaplan–Meier survival analysis and Cox regression models.

Results

PRRT showed only mild hematological and renal toxicity, with most adverse events being low-grade (87%). OS was significantly shorter in patients with WHO grade III meningiomas (10 months) compared to grade I (not reached, HR 4.77, p < 0.01) and grade II (47 months, HR 4.05, p = 0.01). Similarly, PFS was shorter in patients with WHO grade III meningiomas (4.5 months) compared to grade I (17 months, HR 6.47, p < 0.001) and grade II (17 months, HR 2.71, p = 0.02). In multivariable analysis, only higher WHO grade was an independent predictor of disease progression, while baseline PET and laboratory parameters showed no consistent association. Furthermore, increase of SSTR-positive tumor volume in follow-up PET was associated with shorter PFS (HR 1.02, p = 0.02).

Conclusion

PRRT is a safe treatment option and appears to have a favourable effect in patients with recurrent meningiomas. WHO tumor grade is the strongest predictor of PFS and OS, while baseline PET parameters appear to have no prognostic value.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MeningiomaReceptors, SomatostatinOctreotideMeningeal NeoplasmsSafetyHumansFemaleMaleMiddle AgedAgedAdultPrognosisTreatment OutcomeRetrospective StudiesRecurrenceRadiopharmaceuticalsNeoplasm Recurrence, Local

Stichwörter der Autor:innen

DOTATOCLu177MeningiomaPRRTPeptide receptor radionuclide therapySSTR

Substanzen

Receptors, SomatostatinOctreotideRadiopharmaceuticals

Autor:innen und Institutionen

  • Department of Nuclear Medicine, University Hospital Würzburg, Oberdürrbacherstraße 6, 97080, Würzburg, Germany. Hasenauer_N@ukw.de.
  • Department of Nuclear Medicine, University Hospital Würzburg, Oberdürrbacherstraße 6, 97080, Würzburg, Germany.
  • Department of Radiation Oncology, University Hospital Wuerzburg, Würzburg, Germany.
  • Department of Nuclear Medicine, University Hospital, Ludwig-Maximilians-Universitaet Muenchen, Munich, Germany.

ORCID-Profile: Natalie Hasenauer

Förderung

  • Universitätsklinikum Würzburg

Zitieren

APA

Hasenauer, N., Müller, M., Hänscheid, H., Serfling, S. E., Michalski, K., Heinrich, M., Polat, B., Buck, A. K., Werner, R. A., & Hartrampf, P. E. (2025). SSTR-directed peptide receptor radionuclide therapy for recurrent meningiomas: analysis of safety, efficacy and prognostic factors. European Journal of Nuclear Medicine and Molecular Imaging, 53(1), 116-127. https://doi.org/10.1007/s00259-025-07336-6

Vancouver

Hasenauer N, Müller M, Hänscheid H, Serfling SE, Michalski K, Heinrich M, et al. SSTR-directed peptide receptor radionuclide therapy for recurrent meningiomas: analysis of safety, efficacy and prognostic factors. European Journal of Nuclear Medicine and Molecular Imaging. 2025;53(1):116-127. doi:10.1007/s00259-025-07336-6

BibTeX
@article{Hasenauer2025,
  author = {Hasenauer, Natalie and Müller, Miriam and Hänscheid, Heribert and Serfling, Sebastian E and Michalski, Kerstin and Heinrich, Marieke and Polat, Bülent and Buck, Andreas K and Werner, Rudolf A and Hartrampf, Philipp E},
  title = {SSTR-directed peptide receptor radionuclide therapy for recurrent meningiomas: analysis of safety, efficacy and prognostic factors},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2025},
  volume = {53},
  number = {1},
  pages = {116--127},
  doi = {10.1007/s00259-025-07336-6}
}
Kostenlos starten →